Development and explainable AI-driven characterization of a prognostic model for haploidentical transplantation

Rohtesh S Mehta1, Yosra M Aljawai2, Partow Kebriaei2

  • 1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. rmehta1@mdanderson.org.

NPJ Digital Medicine
|March 2, 2026
PubMed

We developed a novel, explainable artificial intelligence (AI)-driven prognostic model using a contemporary single-centre cohort of 668 patients undergoing haploidentical hematopoietic cell transplantation (HCT) with post-transplantation cyclophosphamide (PTCy) prophylaxis (2015-2024) to define the hierarchy of prognostic factors for overall survival. Employing a gradient boosting machine with explainable AI techniques, including partial dependence plots and surrogate decision trees, revealed a non-linear, U-shaped effect of donor age, with optimal outcomes for donors in their late 20 s to early 40 s. Recipient age was the dominant risk factor, modulated by donor age and HLA factors. HLA-DPB1 non-permissive mismatches were the most significant HLA factor (9.6% 3-year OS reduction), followed by HLA-B leader and HLA-DQB1 mismatches, with no independent effect of HLA-DRB1. The model accurately stratified patients into distinct risk quartiles, with 3-year survival ranging from 75% in the lowest-risk to below 20% in the highest-risk group. Critically, simulation analyses demonstrated that optimal donor selection (age 30, no key HLA mismatches) could shift a patient's risk profile by approximately one full quartile, significantly improving survival (e.g., Q3 patients from 20% to 50% 3-year OS). This study provides a practical, data-driven framework for personalized donor selection in the modern HCT era. Future multi-center validation studies are warranted.

Related Concept Videos

Hematopoiesis01:21

Hematopoiesis

The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
9.4K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
4.2K
Lineage Commitment01:21

Lineage Commitment

Commitment is the  process whereby stem cells:
4.5K
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
4.0K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
1.9K